This R33 Project Grant for $582,638, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund the development and preclinical testing of a novel immunocytokine therapy called F5111-IC. The goal is to suppress the formation of inhibitor antibodies that can complicate clotting factor replacement therapy for patients with hemophilia A and B. The proposed research will validate the targeted immunomodulatory effects of F5111-IC in multiple preclinical models of hemophilia, with the aim of identifying an optimal treatment protocol that can promote durable immune tolerance with acceptable safety profiles. If successful, this technology may have broader applications for managing anti-drug antibodies associated with other biologic treatments and conditions such as antibody-mediated hyperacute rejection in transplantation.
Generated 2/25/25, 5:34 AM